Pipeline
Our Key Focus: Developing a Versatile Antibiotic to Prevent and Treat Pseudomonas Aeruginosa, Various Bacterial and Fungal Infections, and Biofilms in Cystic Fibrosis.
CSAs are resilient in challenging environments:
- Maintain activity within cystic fibrosis mucus environments, demonstrating low minimum inhibitory and bactericidal concentrations (mic/mbc).
- Effective against bacterial strains that have developed resistance to polyanionic antiseptics and conventional treatments.
- Active against multiple CF-related pathogens (low mic/mbc)y
- Active against biofilms: bacterial and fungal
We also actively develop novel treatments for rare diseases and biodefense pathogens.
Lets Get in Touch!
- 1 (702) 285-5740
- info@kinnearpharma.com
- Fax: (877) 686-3318
- 3960 Howard Hughes Parkway, Las Vegas, NV, 89169
Follow now